Some Molecular and Clinical Aspects of Genetic Predisposition to Malignant Melanoma and Tumours of Various Site of Origin

Table 8 Lys751Gln/Gly156Gly genotypes among melanoma and control groups

Lys751Gln	Gly156Gly	Melanoma (MM)	Newborns	95% CI	p	OR
		(n = 424)	(n = 1052)
AA	AA	56 (13.2%)	157 (14.9%)	-	n.s.	0.9
AA	CA	70 (16.5%)	182 (17.3%)	-	n.s.	1
AA	CC	19 (4.5%)	62 (5.9%)	-	n.s.	0.7
AC	AA	7 (1.65%)	25 (2.4%)	-	n.s.	0.7
AC	CA	130 (30.66%)	318 (30.2%)	-	n.s.	1
AC	CC	66 (15.57%)	153 (14.6%)	-	n.s.	1.1
CC	AA	2 (0.50%)	2 (0.2%)	-	n.s.	2.5
CC	CA	9 (2.12%)	36 (3.4%)	-	n.s.	0.6
CC	CC	65 (15.3%)	117 (11.12%)	1.044–2.006	0.03 (0.18)	1.4
CC	CC	MM = 50¹	117 (11.12%)	-	n.s.	1.1
		(n = 172)
		21 (12.2%)
CC	CC	MM>50¹	117 (11.12%)	1.170–2.491	0.007 (0.042)	1.7
		(n = 250)
		44 (17.6%)

ISSN: 1897-4287